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The pathophysiology of cutaneous lupus erythematosus
(CLE) encompasses the complex interactions between
genetics, the environment, and cells and their products.
Recent data have provided enhanced understanding of
these interactions and the mechanism by which they
cause disease. A number of candidate genes have been
identified which increase the risk of developing CLE.
Ultraviolet radiation, the predominant environmental
exposure associated with CLE, appears to initiate CLE
lesion formation by inducing apoptosis, precipitating
autoantigen presentation, and promoting cellular
production of specific cytokines. Autoantibodies are a
well-known entity in CLE, but their exact role remains
unclear. Finally, cells ranging from native skin cells to
innate and adaptive immune cells produce cytokines
and other molecules and play specific roles in lesion
formation and perpetuation. Native skin cells implicated
in CLE include keratinocytes and endothelial cells.
Innate immune cells crucial to CLE pathophysiology
include dendritic cells and neutrophils. The primary
adaptive immune cells thought to be involved include
Th1 cells, Th17 cells, cytotoxic T cells, and invariant
natural killer T cells. Though the pathophysiology of
CLE has yet to be fully characterized, current research
provides direction for future research and therapies.Complement
Introduction
Cutaneous lupus erythematosus (CLE) is an auto-
immune disease with various subsets and wide-ranging
clinical manifestations. The primary CLE subsets are dis-
coid lupus erythematosus (DLE), subacute cutaneous
lupus erythematosus (SCLE), and acute cutaneous lupus
erythematosus (ACLE). While the skin manifestations of* Correspondence: werth@mail.med.upenn.edu
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years, the pathophysiology of CLE remains to be fully
characterized. Recent increased recognition of, and inter-
est in, this disease has resulted in enhanced understanding
of the etiology of CLE. The initiation and perpetuation of
CLE involves genetic risk factors, environmental expo-
sures, and cellular components of the skin and the innate
and adaptive immune systems [1].Genetics
Major histocompatibility complex
Certain major histocompatibility complex (MHC) class I
and II alleles that may confer susceptibility to CLE in-
clude HLA B8, DR3, DQA1, and DRB1. HLA DR3 and
DR2 are associated with positivity for Ro-SSA autoanti-
bodies and SCLE. Specific alleles of HLA DQA1 and
DRB1 appear to be associated with DLE [2, 3]. MHC
polymorphisms that increase susceptibility to disease
may do so by allowing escape of autoreactive T lympho-
cytes from negative selection in the thymus. This failed
purging of autoreactive cells may be mediated by de-
creased affinity of specific MHCs for autoreactive T-cell
receptors, the interaction of which is vital to this selec-
tion process. Furthermore, these MHC polymorphisms
may have decreased ability to select for regulatory T cells
(Tregs) that can increase self-tolerance [4].A C1QA single-nucleotide polymorphism (SNP) has
been found to be highly associated with SCLE and lower
C1 serum protein levels. Congenital C1q deficiency is
highly associated with photosensitive systemic lupus ery-
thematosus (SLE). While the mechanism is unknown,
C1q may be involved in clearance of post-apoptotic im-
munogenic material. However, studies in C1q-deficient
mice did not show a difference in clearance of apoptotic
keratinocytes (KCs) after ultraviolet (UV) radiation com-
pared with wild type. Chronic UV exposure did not
result in production of autoantibodies either in C1q-
deficient mice [5]. Other complement components mayAccess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise credited.
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in C2 and C4 have been found to be associated with
CLE-like skin lesions. This may be related to failure of
fixation of immune complexes. There is, however, little
evidence for either of these proposed mechanisms [6, 7].
Tumor necrosis factor-α
Tumor necrosis factor (TNF)-α, a primary cytokine in
inflammatory cascades, promotes release of secondary
cytokines and recruitment of immune cells, ultimately
leading to tissue destruction. It may also promote
presentation of autoantigens at the cell surface and sub-
sequent autoreactivity [8, 9]. The TNF-α promoter poly-
morphism -308A is associated with SCLE but not DLE.
In addition, −308A polymorphism is associated with
HLA-DR3. The promoter polymorphism appears to in-
crease transcription in vitro when transfected cells are
exposed to UVB radiation in the presence of interleukin
(IL)-1α, a photoinduced cytokine. The difference may be
due to differential binding of transcription factors at
promoter variants [8].
TYK2, IRF5, and CTLA4
A panel of SNPs previously implicated in SLE risk were
analyzed for CLE risk. TYK2, IRF5, and CTLA4 are asso-
ciated with CLE while GIMAP5, FCGR2A, and PDCD1
are not. However, clinical characteristics were not asso-
ciated with specific genotypes of TYK2 or IRF5. TYK2 is
associated with DLE. TYK2, a Janus kinase, binds to the
interferon (IFN)-α receptor 1 and is involved in cytokine
signaling. Activation of TYK2 leads to expression of
IFN-regulated genes [10].
IRF5 is associated with DLE and SCLE. IRF5 is a tran-
scription factor which regulates type I IFNs and has
broad effects on the immune system. Certain IRF5 vari-
ants may cause prolonged inflammatory response and
disrupt immune tolerance. Variants causing increased
expression of IRF5 likely lead to increased production of
type I IFNs and excessive pro-inflammatory response.
Type I IFNs recruit T cells into skin lesions of patients
with CLE. Increased expression of IRF5 is also seen in
UV-irradiated skin, which supports the role of this tran-
scription factor in the pathophysiology of CLE [10].
CTLA4 is also associated with DLE. CTLA4 regulates
T-cell activation and survival. Variants in CTLA4 may
prevent appropriate limitation of T-cell response in
inflammation [10].
ITGAM
ITGAM polymorphisms are associated with DLE and SLE,
conferring a greater risk for DLE than for SLE. The risk
for DLE is independent of the risk for systemic involve-
ment. ITGAM encodes the α-chain of αMβ2-integrin, a cell
surface receptor involved in inflammation. αMβ2-integrinis found on the surface of neutrophils, macrophages, and
dendritic cells and is involved in leukocyte adhesion,
phagocytosis, and apoptosis. Its ligands include comple-
ment 3 cleavage fragment and ICAM-1. The mechanism
of increased risk for DLE/SLE with certain variants may
be due to abnormal removal of apoptotic cells and im-
paired phagocytosis, leukocyte trafficking, and immune
regulation [11].
TREX1
Familial chilblain lupus is a variant of CLE characterized
by painful, ulcerating, and inflammatory acral papules
and nodules. The lesions are precipitated by cold and
wet exposure. The condition is associated with arthral-
gias. A heterozygous missense mutation in TREX1 was
found to be responsible for familial chilblain lupus. Fa-
milial chilblain lupus is thus inherited in an autosomal
dominant fashion. TREX1 is a gene encoding the 3’-5’
repair exonuclease 1, which catalyzes the excision of
nucleoside monophosphates from 3’ termini of DNA.
TREX1 functions as a homodimer, the enzymatic activity
of which is decreased in the heterozygous state. The het-
erozygous missense mutation does decrease TREX1 ac-
tivity but does not have a dominant-negative effect.
TREX1 appears to be important in caspase-independent
apoptosis. Specifically, TREX1 is important for granzyme
A-mediated cell death, which is impaired in the hetero-
zygous state. Defective apoptosis may lead to loss of self-
tolerance and autoreactive immune cells. Furthermore,
given that TREX1 functions to degrade DNA, the mis-
sense mutation may be responsible for defective DNA
degradation during apoptosis, leading to abnormal clear-
ance of DNA and induction of autoimmunity [12, 13].
However, while in some instances TREX1 may promote
apoptosis, TREX1 may actually play a role in preventing
apoptosis in cells exposed to genotoxic stress from
UV light and chemical genotoxins as demonstrated by
Christmann et al. [14]. These divergent findings indicate
the varied and setting-dependent function of TREX1.
Recent data have shed light on additional aspects of
TREX1 in autoimmune disease. TREX1-deficient mice,
known to develop type I IFN-dependent autoimmunity,
display upregulation of type I IFN-dependent genes in
the skin and cutaneous deposition of immunoglobulins
and complement [15]. TREX1 also appears to regulate
macrophage response to pro-inflammatory stimuli. In
TREX1 deficiency, macrophages increase production of
TNF-α and type I IFNs, increase presentation of the
costimulatory molecule CD86 and antigens to CD4+ T
cells, and show decreased ability to clear apoptotic cells
[16]. Taken together, these findings suggest mutations in
and dysregulation of TREX1 have the potential to lead to
inappropriate activation of the immune system and de-
velopment of autoimmunity.
Achtman and Werth Arthritis Research & Therapy  (2015) 17:182 Page 3 of 10Ultraviolet radiation
Photosensitivity
Photosensitivity in CLE varies widely in the literature.
Photosensitivity has been found to range from 27 % to
100 % in SCLE and from 25 % to 90 % in DLE. These
varied results are accounted for by differences in patient
perception of photosensitivity as well as differences in
techniques used in photoprovocation studies. Patient-
reported history of photosensitivity does not predict a
positive reaction to phototesting. Skin lesions cannot al-
ways be reproduced during photoprovocation tests, and
photosensitivity does not necessarily indicate the forma-
tion of photoinduced lesions. Rather, photosensitivity en-
compasses a wide range of symptoms in response to
light [17].
Apoptosis
Apoptosis is a normal part of KC development. Under
normal conditions, apoptosis occurs in the granular cell
layer of the epidermis at the interface with the stratum
corneum. External factors, however, are able to induce
premature apoptosis of KCs. Basilar cells are more
resistant to induction of premature apoptosis, while
suprabasilar KCs much more readily undergo premature
apoptosis under certain conditions. It has been shown
that UV light can cause KC apoptosis by multiple mech-
anisms, including generation of reactive oxygen species,
DNA damage, and activation of Fas and FasL, among
others [9].
UV radiation has been shown to induce specific pat-
terns of KC apoptosis in various subsets of CLE. Norris
et al. [18] demonstrated an elevated number of apop-
totic cells in the basal zone of the epidermis of DLE le-
sions. In contrast, SCLE lesions showed increased
apoptotic cells in the suprabasilar epidermis. Normal
skin showed no apoptosis. Kuhn et al. [19] found an
abnormal increase in the number of apoptotic cells in
UV-induced CLE lesions, which might reflect an accu-
mulation due to impaired clearance. The investigators
hypothesized that this may lead to secondary necrosis of
the uncleared apoptotic cells and the release of pro-
inflammatory molecules leading to tissue inflammation
and autoimmunity. The etiology of impaired clearance is
unclear. However, decreased phagocytosis of apoptotic
material by macrophages derived from SLE patients has
been demonstrated, which may be the case in CLE as
well [20]. Chen et al. [21] demonstrated that autoanti-
bodies to certain macrophage receptors may be respon-
sible for decreased clearance of apoptotic material. In
contrast to these findings, however, Reefman et al. [22, 23]
found no increase in apoptosis induction, clearance of
apoptotic cells, or secondary necrosis in UVB-irradiated
skin of SLE patients when compared with healthy con-
trols. This disparate finding may be due to differences inthe technique used to detect apoptotic cells. In SLE
patients, the investigators also found inflammatory lesions
in the vicinity of apoptotic cells and increased numbers
of macrophages. They hypothesized that macrophage
clearance of apoptotic material may represent a pro-
inflammatory process accounting for the difference in re-
sponse to UVB radiation despite no difference in rate of
apoptosis or apoptotic cell clearance.
Autoantigens and autoantibodies
UV radiation-induced apoptosis causes relocalization of
autoantigens [18]. Lefeber et al. [24] found that UV radi-
ation induces relocalization to the cell surface of SSA/Ro,
SSB/La, RNP, and Sm. Antibodies to these antigens are
common in CLE. Subsequent studies demonstrated that
Ro and La relocalize to apoptotic bodies of UV-irradiated
KCs undergoing programmed cell death (Fig. 1) [25].
Findings by Lawley et al. [26] suggest apoptosis, however,
may not be necessary for presentation of these autoanti-
gens at the cell surface after exposure to UV light.
Cells and cytokines
UV radiation causes not only apoptosis and autoantigen
presentation but also recruitment of immune cells and
production of cytokine cascades. UV light is clearly re-
sponsible for the generation of inflammation in both
normal skin and skin from patients with CLE. The
mechanism of increased susceptibility to inflammation
and damage by UV radiation is still far from clear. Skin
infiltration by leukocytes and other immune cells in re-
sponse to UV light are crucial to the development of
CLE lesions. T lymphocytes are the predominant cell type
found in lesions, though plasmacytoid dendritic cells
(pDCs) and myeloid dendritic cells are also increased. UV
radiation mediates the production and release of cytokines
and chemokines, promoting inflammation and recruit-
ment of immune cells [27, 28].
More specifically, UVB induces KC release of IL-1 and
TNF-α, primary cytokines in the inflammatory cascade
(Fig. 1). UVB radiation works synergistically with IL-1α
to increase production of TNF-α. TNF-α also appears to
increase its own production in an autocrine manner.
These cytokines subsequently mediate the release of sec-
ondary cytokines. This cytokine cascade, recruitment of
immune cells, inflammation, and tissue destruction ultim-
ately result in the photoinduced lesions of CLE [9, 29].
Autoantibodies
The role of autoantibodies in CLE is uncertain. Whether
these autoantibodies play a role in the pathogenesis of
the disease or are merely non-acting byproducts of im-
munity gone awry is unclear. These antibodies, however,
may prove to be valuable as prognostic indicators.
Fig. 1 Keratinocytes (KCs) produce cytokines and pro-inflammatory molecules in response to ultraviolet (UV) radiation and other damage. These
cytokines recruit and activate members of the innate immune system, including macrophages, myeloid dendritic cells (mDCs), and plasmacytoid
dendritic cells (pDCs). Endothelial cells also recruit cells from the innate immune system through adhesion molecules and glycosaminoglycans
(GAGs). Endogenous DNA from apoptosis and neutrophil extracellular traps enhance cytokine production by pDCs. pDCs produce interferon
(IFN)-α, which recruits members of the adaptive immune system, including Th1 and cytotoxic T cells (CTLs). Th1 cells produce IFN-γ that activates
macrophages and CTLs and upregulates its own production. CTLs prime KCs and other cells for apoptosis through granzyme B (GrB), which
activates caspases in the target cells. KCs recruit invariant natural killer T cells (iNKTs) through enhanced expression of the antigen-presenting
molecule CD1d. iNKTs produce IFN-γ among other cytokines. Various immune cells promote differentiation and activity of Th17 cells through
the production of IL-6. Th17 cells produce IL-17. Activity of these cells and cytokines lead to lesion formation and perpetuation characteristic of
cutaneous lupus erythematosus. MMP, matrix metalloproteinase; TLR, Toll-like receptor
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Various autoantibodies have been found in patients with
CLE. The role of these autoantibodies in CLE is un-
known. Anti-Ro/SSA and anti-La/SSB are such auto-
antibodies closely associated with CLE. Biazar et al. [30]
found that anti-Ro/SSA antibodies were detected in
72.1 % of patients with SCLE, 47.4 % of patients with
ACLE, and 22 % of patients with DLE. It was also noted
that patients with ACLE and positive for anti-Ro/SSA
antibody reported significantly more photosensitivity
than patients who were negative for the antibody; how-
ever, photoprovocation did not reveal a difference in
photosensitivity between these groups. Anti-La/SSB anti-
bodies were detected in 36.2 % of patients with SCLE,
27.5 % of patients with ACLE, and 7.0 % of patients with
DLE. No difference was found in reported photosensitivityor photoprovocation for patients positive or negative for
anti-La/SSB.
While the role of autoantibodies is unknown, Li et al.
[31] and Wasicek and Reichlin [32] were able to demon-
strate clustering of clinical manifestations with common
antibodies in patients with various subsets of LE, including
cutaneous and systemic. The patients with both anti-Ro/
SSA and anti-La/SSB showed the highest prevalence of
discoid rash, photosensitivity, and hematological involve-
ment. Patients with anti-RNP, anti-Sm, and anti-aPL
antibodies demonstrated high prevalence of malar rash
among other clinical manifestations. Both of these group-
ings negatively correlated with renal involvement. These
studies also confirmed previous reports that anti-Ro/SSA
alone is a risk factor for nephritis [31, 32]. While these
findings do not define a role for these antibodies in the
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Immunoglobulin isotype
A recent study by Jost et al. [33] found that immuno-
globulin (Ig)G, IgM, and IgA anti-nuclear antibodies are
elevated in SLE compared with DLE. The ratio of IgG to
IgM is also increased in SLE compared with DLE. The
authors suggest that the higher ratio represents in-
creased class-switching and enhanced humoral response
in SLE compared with DLE. Additionally, IgM anti-
nuclear antibodies may help to counteract the produc-
tion of IgG anti-nuclear antibodies and their deleterious
effects by decreasing dendritic cell activation and acting
as competitive inhibitors by targeting the same nuclear
antigens. This may ultimately prevent systemic spread of
disease in DLE.
Cells and their products
Keratinocytes
KCs are the primary apoptotic cells in CLE. As stated
earlier, apoptosis and impaired clearance of apoptotic
cells seem to be important in the development of CLE.
KCs in CLE may be more susceptible to apoptosis.
Toberer et al. [34] recently demonstrated enhanced ex-
pression in CLE lesions of Fas (CD95), a death receptor
expressed on the cell surface that mediates the extrinsic
pathway for apoptosis. TNF-related apoptosis-inducing
ligand (TRAIL), a pro-apoptotic protein, is also enriched
in the skin of CLE patients [35]. The KC receptor which
mediates TRAIL apoptosis, TRAIL-R1, is also signifi-
cantly enriched. Furthermore, TRAIL-R4, a TRAIL re-
ceptor which has anti-apoptotic properties, appears to
be decreased. IFN-α enhances the expression of TRAIL
by KCs, which underlines the importance of the interac-
tions between KCs and IFN-α-producing pDCs in creat-
ing a pro-apoptotic environment [34, 35].
KCs found in CLE lesions express higher levels of re-
ceptors for IL-18, which is itself upregulated in lesions.
KCs from CLE appear to be more susceptible to apop-
tosis when exposed to IL-18. When exposed to IL-18,
these KCs also show higher levels of TNF-α expression.
IL-12, a cytokine that has been shown to protect KCs
from apoptosis and is upregulated in healthy skin in
response to IL-18, is downregulated in KCs from CLE
lesions [36].
In addition to their role as apoptotic cells, KCs are in-
volved in a range of inflammatory stimuli crucial to the
development of CLE. KCs, as stated previously, are re-
sponsible for the production of IL-1 and TNF-α, primary
cytokines in the inflammatory cascade. These primary
cytokines have a wide array of effects, including activa-
tion of antigen-presenting cells, induction of adhesion
molecules, and recruitment of immune cells [9, 29].KCs have also recently been found to express type III
IFNs or IFN-λ. IFN-λ shares many functional similarities
with type I IFNs, especially in terms of antiviral im-
munity. KCs produce high levels of IFN-λ1 in response
to immunostimulatory nucleic acids, such as those from
apoptotic cells. IFN-λ acts primarily on epithelial cells, and
epithelial cells respond by producing pro-inflammatory
cytokines like CXCL9, which enhances recruitment of im-
mune cells (Fig. 1). In addition to being enriched at lesional
sites, IFN-λ is also elevated in the serum of CLE patients
with active lesions [37].
KC production of matrix metalloproteinases (MMPs)
may also play a role in CLE. MMPs are enzymes which
degrade components of the extracellular matrix and
basement membrane. They are also implicated in cell
growth, apoptosis, tissue repair, angiogenesis, inflamma-
tion, and immunity. While elevated levels of specific
MMPs have been found in the serum of SLE, MMPs are
less well characterized in CLE. Jarvinen et al. [38] found
enhanced expression of MMP10 in basal KCs of CLE le-
sions. In animal models, elevated levels of MMP10 indi-
cate impaired wound healing, and Jarvinen et al. [38]
hypothesized that enhanced MMP10 may contribute to
irregular matrix degradation in CLE. MMP7, which has
been implicated in apoptotic pathways, is also enriched
in basal KCs of CLE lesions. Despite the high levels of
MMPs, inhibitors of MMPs, such as TIMP1, were not
overexpressed, suggesting overall dysregulation of MMP
activity. Interestingly, there was no difference between
subtypes of CLE in terms of MMP expression [38].
KCs are responsible for production of high mobility
group box 1 (HMGB1), a DNA binding protein found in
most cells that also functions as a pro-inflammatory
molecule extracellularly. HMGB1 is released by KCs in
response to damage, such as UV radiation, or as part of
apoptosis in CLE but not in healthy skin. It increases
IFN-α production by pDCs (Fig. 1). Furthermore,
HMGB1 may also be partially responsible for the im-
paired uptake of apoptotic KCs as it inhibits phosphati-
dylserine, which reduces phosphatidylserine-mediated
phagocytosis. HMGB1 and its associated DNA may be
taken up by immune cells and presented at lymph nodes
to T and B cells, which may enhance autoimmunity [39].
KCs as well as endothelial cells (ECs) express adhesion
molecules in response to damage and other stimuli.
These adhesion molecules mediate migration of inflam-
matory immune cells. UV radiation is a known inducer
of adhesion molecule expression and, in KCs, UV radi-
ation specifically induces expression of ICAM-1. Ele-
vated levels of soluble adhesion molecules have also
been detected in CLE. Soluble ICAM-1 and VCAM-1
are elevated in the serum of both SCLE and SLE and are
positively correlated with Ro/SSA and La/SSB anti-
bodies. High levels of E-selectin, an adhesion molecule
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Endothelial cells
Cutaneous endothelial cells are responsible for produc-
tion of a variety of factors which have been implicated in
the pathogenesis of CLE. Interferon-induced guanylate-
binding protein 1 (GBP1), a mediator of angiostasis in
inflammation, is released by ECs in response to IFN-α
and IFN-γ (Fig. 1). GBP1 appears to be a marker of
pro-inflammatory microenvironments and functions to
inhibit angiogensis and EC proliferation, spread, and mi-
gration. GBP1 has been detected in CLE lesions but not
healthy skin. However, it is unknown whether GBP1 is
merely a marker of inflammation or plays a role in CLE
lesion formation and perpetuation [41].
Glycosaminoglycans (GAGs) have been implicated in
CLE. GAGs produced by ECs and fibroblasts may func-
tion as pathogen-associated molecular patterns (PAMPs)
and provide an inflammatory signal for sterile injury.
GAGs are found in the dermal mucin that accumulates
in CLE. Specifically, hyaluronic acid (HA) and chondro-
itin sulfate are found in the mucin deposits. GAGs can
have both pro- and anti-inflammatory effects. For ex-
ample, low molecular weight HA activates macrophages
and dendritic cells and recruits certain immune cells
and chondroitin sulfate promotes neutrophil activation.
In contrast, high molecular weight HA appears to pro-
tect tissues from inflammation. UVB radiation, however,
induces upregulation of genes expressing hyaluronidases
and creates reactive oxygen species that may convert
anti-inflammatory high molecular weight HA into pro-
inflammatory fragments. HA fragments have been shown
to activate immune cells such as dendritic cells and mac-
rophages via Toll-like receptor (TLR)2 and TLR4. The
accumulation of GAGs in dermal mucin may be acting to
further perpetuate inflammation in CLE [42].
Neutrophils and dendritic cells
Neutrophils have been implicated in the pathogenesis of
CLE. Neutrophils defend against microbial invasion by
forming neutrophil extracellular traps (NETs), structures
composed of chromatin fibers and associated bacteri-
cidal proteins. Neutrophils undergo NETosis in response
to microorganisms, cytokines, and other stimuli. NETs
present double-stranded DNA and other factors such as
LL37 that may play a part in inducing autoimmunity in
LE. NET forming neutrophils are found in CLE lesions
where they are concentrated at the dermoepidermal
junction (DEJ), blood vessels, and adnexae. In addition,
antibodies found in LE may increase NETosis in IFN-α
primed neutrophils. Villanueva et al. [43] recently de-
scribed a subset of reactive neutrophils found in patients
with SLE. Named low-density granulocytes (LDGs),these neutrophils show upregulation of gene products
involved in the inflammatory response, such as LL37
and others. LL37 is associated with NETs in the skin and
microvesicles in serum of patients with CLE [43, 44]. It
has been shown to convert endogenous DNA into po-
tent agonists of TLRs on pDCs, which subsequently en-
hances type I IFN production (Fig. 1) [43]. LL37 also
acts as a chemoattractant for a variety of immune cells
and mediates the release of inflammatory cytokines from
endothelial cells [43]. NET formation is enhanced in
LDGs, which in turn increases externalization of puta-
tive autoantigens and immunostimulatory molecules
[43]. Due to NET formation, presentation of putative
autoantigens, and production of inflammatory signals,
subsets of neutrophils unique to LE patients may be im-
portant in the pathogenesis of skin lesions.
pDCs, another component of the innate immune sys-
tem, play an important role in the pathogenesis of CLE.
pDCs are the main producers of type I IFNs, which me-
diate the inflammatory cascades in CLE. High numbers
of type I IFN producing pDCs have been found in CLE
lesions, while pDCs appear to be absent from normal
skin. Elevated type I IFN production has been demon-
strated by measuring expression of MxA, a type I IFN-
inducible molecule. While pDCs normally produce type
I IFNs in response to infection, it has been hypothesized
that the high levels produced in CLE lesions may be in
response to increased apoptosis, autoantibodies, and
other immune cells, such as neutrophils, as mentioned
above. Serum from LE patients combined with apoptotic
cells from various lines has been shown to stimulate
IFN-α production in pDCs in vitro [45]. pDCs are likely
recruited to lesional sites due to inflammation and ex-
pression of chemokines, complement components, and
adhesion molecules. For example, pDCs express high
levels of L-selectin, and dermal endothelial cells in LE le-
sions express PNAd, a ligand for L-selectin. There are
distinct subsets of pDCs in LE, ones that localize to the
dermis and ones that localize to the DEJ. Dermal pDCs
appear to mediate recruitment of Th1 T cells, while
junctional pDCs recruit cytotoxic T cells [46, 47].
TLRs play a role in initiating pDCs as well as neutro-
phil activity. It has been shown in SLE that activation of
pDCs through TLR7 and TLR9 by endogenous nucleic
acids is a crucial part of the pathogenesis [48]. Activa-
tion through these TLRs leads to production of IFN-α
and subsequent inflammatory events. Neutrophils also
express these TLRs and are activated by TLR7 and TLR9
agonists. Lupus-prone (NZBxNZW)F1 mice develop
chronic skin lesions resembling human CLE lesions after
tape stripping. Antagonizing TLR7 and TLR9 results in
a significantly more normal cutaneous response to tape
stripping, suggesting that these TLRs may be required
for initiation and maintenance of CLE lesions [48].
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pact the inflammatory cell infiltrate, suggesting that the
stimuli for cell migration are separate from the stimuli
for cytokine production. Guiducci et al. [48] hypothesize
that while the initial reaction to cutaneous insult is nor-
mal in CLE, it is the prolongation of inflammatory stim-
uli and response that is responsible for the characteristic
lesions in CLE. Immune complexes found at the DEJ
and circulating autoantibodies may prolong stimulation
of these receptors, leading to chronic cutaneous lesions.
Impaired clearance of damaged and apoptotic KCs as
described earlier may also be a source for prolonged ac-
tivation of these TLRs.
B cells
B cells act not only as antigen-presenting cells but also
produce autoantibodies and secrete cytokines in auto-
immune diseases such as CLE [49]. In DLE, specifically,
it has been demonstrated that there is a higher density
of B lymphocytes circulating peripherally and in lesional
skin [50–52]. Interestingly, however, B cell-depleting
therapies seem to lack efficacy in chronic cutaneous
lupus erythematosus, such as DLE, while showing some
effect in ACLE and SCLE [49]. Vital et al. [53] recently
demonstrated a significant improvement after rituximab
therapy in a proportion of patients with ACLE. In con-
trast, no patients with chronic cutaneous lupus erythe-
matosus responded to B cell-depleting therapy, with
some patients even experiencing flares in cutaneous dis-
ease. In light of these findings, the authors hypothesized
that even if B cells are important in the initiation of
cutaneous disease, they may not be essential for the
perpetuation. As to why B cell-depleting therapy may
provoke flaring of cutaneous disease, it may be that B
cell-produced IL-10, an anti-inflammatory cytokine, is
decreased after rituximab or that B-cell lysis may be
pro-inflammatory [53]. Exactly how B cells participate in
the pathophysiology of CLE has yet to be elucidated, but
possible mechanisms include enhancement of auto-
immune helper T cells and local secretion of autoanti-
bodies, opsonization, and subsequent activation of the
complement system [52, 54].
Th1 cells
The inflammation in CLE appears to be predominantly
Th1 mediated. Type I IFNs produced by pDCs recruit
Th1 lymphocytes to CLE lesions by upregulating pro-
duction of IP10/CXCL10 by KCs and other skin cells
(Fig. 1). IP10/CXCL10 is a ligand for CXCR3, which is
preferentially expressed by Th1 cells and therefore medi-
ates the migration of Th1 cells to lesional sites. Ligands
for CXCR3, like IP10/CXCL10, are the most abundantly
expressed chemokine family members in CLE and cor-
relate with the presence of pDCs and lymphocytes.pDC-produced IFN-α has been shown to induce Th1
differentiation and may also cause Th2 cells to convert to
a Th1 phenotype. Th1 cells themselves produce IFN-γ,
which perpetuates the upregulation of CXCR3 ligands and
mediates downstream inflammatory effects responsible for
lesion formation and persistence. IP10/CXCL10 and other
Th1-specific ligands have also been shown to be potent
antagonists of CCR3 expressed on Th2 cells. CXCR3-
expressing lymphocytes are decreased in the blood of pa-
tients with CLE, further suggesting active recruitment of
these cells to CLE lesions. Enhanced CCR5+ to CCR3+
lymphocyte ratio, indicating an enhanced Th1 to Th2
ratio, correlates with disease activity as measured by
the Cutaneous Lupus Erythematosus Disease Area and
Severity Index [27, 55, 56].
Th1-produced IFN-γ activates macrophages, enhances
activity of cytotoxic T cells, mediates antiviral immune
activity, and induces differentiation of naive T cells into
Th1 cells. IFN-γ is also able to upregulate its own ex-
pression [57]. The role of IFN-γ in development and
persistence of CLE lesions is also supported by findings
in transgenic mice overexpressing IFN-γ in the epider-
mis. These mice develop a lupus-like syndrome with
autoantibodies and CLE-like skin lesions. IFN-γ-induced
skin lesions from this model and CLE skin lesions ap-
pear to share multiple characteristics, such as similar
dermal infiltrate, KC expression profile, and enhanced
apoptosis. Furthermore, exogenously administered IFN-γ
in humans has been reported to cause LE with pro-
minent CLE lesions. Additionally, depletion of CD4+
T cells with monoclonal antibodies has been shown to
result in significantly decreased disease activity in severe
CLE, highlighting the crucial role of helper T cells in the
pathogenesis of this disease [58].
Th17 cells
The role of Th17 cells is not as clear as those of other
immune cells. Oh et al. [59] showed that expression of
IL-17A, an isoform of IL-17, positively correlated with
expression of IFN-α in CLE lesions compared with
psoriatic skin lesions. IL-17A was presumably expressed
by Th17, though other cell types are known to produce
this cytokine. IL-6, a cytokine involved in inflammation
and differentiation of Th17 cells, is likely responsible in
part for Th17 activity in CLE. The investigators showed
elevated levels of IL-6 in lesional skin. While the source
of the IL-6 was not determined, fibroblasts, macro-
phages, endothelial cells, T cells, and B cells are known
to produce this cytokine in response to IL-1, TNF-α, and
IFNs [59]. Tanasescu et al. [60] also found elevated
expression of IL-17 in the skin of patients with CLE.
IL-17A was elevated in the serum of patients with DLE
and SLE, but not in SCLE. IL-17 F, however, was ele-
vated in SCLE serum. Elevated IL-17A in the serum
Achtman and Werth Arthritis Research & Therapy  (2015) 17:182 Page 8 of 10correlated with IL-17+ lymphocytes in the cutaneous in-
flammatory infiltrate only in DLE. Interestingly, the
presence of anti-Ro/SSA antibodies in the SCLE serum
correlated with enhanced presence of IL-17A+ lympho-
cytes in the skin. There may be an association between
exposure to the Ro antigen and expression of IL-17A
through activation of Th17 cells by dendritic cells [60].
In contrast to these findings, however, Jabbari et al.
[61] found very little evidence of Th17 cells in DLE. The
investigators demonstrated enrichment of Th1 cells and
absence of Th17 cells in DLE lesions. IFN-γ regulated
genes were upregulated whereas IL-17 genes did not
show increased expression. Whether or not Th17 cells
are significant players in CLE has yet to be determined.
Regulatory T cells
Tregs function to inhibit inflammation by secreting in-
hibitory cytokines such as IL-10 and transforming
growth factor-β and by suppressing other T cells through
direct contact. Treg numbers are reduced in CLE le-
sions. However, while in SLE a decrease in circulating
Tregs has been observed, in CLE this does not appear to
be the case. Interestingly, the Treg reduction in lesional
skin of CLE patients is not observed in other inflamma-
tory skin diseases such as atopic dermatitis, psoriasis,
and lichen planus. To explore the etiology of the reduc-
tion of Tregs, Franz et al. [62] tested the response of
Tregs from CLE patients to Fas ligand (CD95L), a mol-
ecule known to induce apoptosis. It has been previously
hypothesized that low numbers of Tregs may be due to
increased susceptibility to apoptosis in response to this
ligand. Franz et al., however, found no evidence of in-
creased susceptibility to apoptosis in patient-derived
Tregs. Furthermore, the investigators found no dif-
ference between CLE-derived and control-derived Tregs in
their ability to suppress conventional T cell proliferation.
Cytotoxic CD8+ T cells
Cytotoxic CD8+ T cells (CTLs) contribute to the inflam-
matory infiltrate found in CLE lesions. These cells ex-
press granzyme B, a serine protease which is able to
prime cells for apoptosis by activating caspases (Fig. 1).
Granzyme B expression is associated with the DEJ infil-
trate in CLE and positively correlates with expression of
IFN-α. IFN-α, presumably produced by pDCs, is able to
stimulate development of CTLs, enhance their cytotox-
icity, and upregulate MHC class I molecules in tissues,
thus making those tissues targets for this type of T cell.
Additionally, increased activity of CTLs appears to be
more associated with the destructive and scarring types
of CLE, such as DLE. Given their presence in CLE le-
sions and production of pro-apoptotic molecules, CTLs
appear to play a role in CLE, though the level of their
significance is not certain [63, 64].Invariant natural killer T cells
Human invariant natural killer T cells (iNKTs) are a sub-
type of T lymphocytes which release Th1- and Th2-like
cytokines, including IFN-γ, TNF-α, IL-4, and IL-10. Due
to the array of cytokines they are able to produce, iNKTs
have a broad spectrum of functionality and are able to
promote or suppress inflammation. iNKTs respond to
lipid antigens presented by CD1d, in contrast to other T
cells which respond to peptides presented by MHC.
CD1d is an antigen-presenting molecule expressed on
epithelial cells like KCs, dendritic cells, and B cells. It
has been shown that trauma upregulates expression of
CD1d on KCs. Lower numbers of circulating iNKTs are
correlated with more severe disease activity of CLE, and
the amount of immunosuppressive therapy does not
seem to influence circulating iNKTs. Hofmann et al.
[65] demonstrated enrichment of iNKTs in the lesions of
all types of CLE and hypothesized that circulating defi-
ciency of iNKTs may be due to active recruitment and
migration to lesional sites. The investigators also found
expression of IFN-γ by iNKTs in lesions. Thus, iNKTs
may contribute to the inflammatory microenvironment
of CLE lesions.Conclusion
CLE is a heterogeneous disease with a pathophysiology
that has yet to be fully characterized. The current under-
standing of CLE risk factors, markers, and cellular com-
ponents can aid in prognostics and the development of
novel therapies. To this end, additional research is
needed to better clarify the mechanism of this disease.
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